ABSTRACT
Background and Aims: Tattoo prevalence has significantly increased over the last decades. Proper tattoo aftercare, such as cleansing, moisturizing, and protection against sunlight, is essential to prevent complications and to keep the beauty of the tattoo. The tolerability, performance, and cosmetic acceptability of two dexpanthenol-containing dermo-cosmetic products, a wash and a sun-care, were investigated on tattooed skin in two separate trials. Methods: Two single-center, exploratory, open-label cosmetic studies were conducted between August and November 2020 to evaluate the dexpanthenol-containing dermo-cosmetic products. In the first study, healthy adults applied the 2.5% dexpanthenol-containing wash right after their tattoo session daily for 14 consecutive days. In the second study, healthy adults applied the 2.5% dexpanthenol-containing sun-care sun protection factor 50+ cream on existing tattoos that were daily exposed to sunlight for 28 consecutive days. Clinical examination by a dermatologist and self-assessment through subject questionnaires were used to assess the tolerability, acceptance, ease of use, and cosmetic outcomes of both products. Additionally, transepidermal water loss and moisturization assessments were performed to evaluate skin hydration after use of the sun-care product. Results: Both study products were well tolerated, and no product related adverse events were reported during the studies. At least 90% of the study participants appreciated the performance of the dexpanthenol-containing wash and sun-care product, including moisturizing properties, relief of unpleasant sensations, and preservation of the cosmetic appearance of the tattoo. For the sun-care, it was shown that its application supported maintaining the skin barrier of tattooed skin, while keeping it hydrated. Conclusion: The 2.5% dexpanthenol-containing wash and sun-care products are well tolerated and appreciated by tattooed subjects. Hence, they represent valid options for tattoo aftercare in line with current recommendations and practice.
ABSTRACT
OBJECTIVES: This aim of this study was to evaluate the potential of staphylococci to develop resistance and cross-resistance to antibiotics following exposure to antiseptics. METHODS: The antibiotic susceptibility profile as well as the antiseptic minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBC) were determined for Staphylococcus epidermidis and Staphylococcus aureus clinical isolates and reference strains (methicillin resistant or not) before and after prolonged exposure to low concentrations of two antiseptics, namely chlorhexidine digluconate (CHG) and octenidine dihydrochloride (OCT). RESULTS: Resistance was observed to both tested antiseptics following exposure. CHG exposure led to increased MICs in five of the six tested strains of S. epidermidis and S. aureus and also led to clinically decreased susceptibility to gentamicin in S. aureus ATCC 43300 (MRSA) and to penicillin and tetracycline in S. aureus ATCC 25923 (MSSA). OCT exposure led to an increased MIC only in S. epidermidis ATCC 12228 (MSSE) and also led to a clinically decreased susceptibility to penicillin in S. aureus clinical strain SAL. One strain (MSSE) showed a four-fold increase in the MIC against CHG. Several strains showed a two-fold increase in the MIC against CHG and only one strain (MSSE) against OCT. CONCLUSION: These results support the urgent need to apply the same administration rules currently accepted for antibiotics to antiseptics in order to preserve the benefits both of antiseptics and antibiotics.
